Glucose, satiety, and body-composition research.
Weight Management Research Stack
The modern GLP-1 / dual / triple agonist research lineup.
Why researchers discuss this grouping
Semaglutide is the single-agonist benchmark. Tirzepatide adds GIP for additional weight effect in trials. Retatrutide adds glucagon-receptor activity for the largest weight-loss readouts to date.
Members
- Semaglutide
GLP-1 agonist — single-receptor benchmark.
- Tirzepatide
GLP-1 + GIP dual agonist.
- Retatrutide
GLP-1 + GIP + glucagon triple agonist.
- Cagrilintide
Amylin analog studied alongside semaglutide (CagriSema).
Shop this stack
Add the full weight management research stack to your cart in one click, or pick individual products below.